Halozyme Therapeutics, Inc. to Post FY2026 Earnings of $5.16 Per Share, Zacks Research Forecasts (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research increased their FY2026 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for the year, up from their previous forecast of $5.08. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share.

A number of other equities research analysts also recently weighed in on the company. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. The Goldman Sachs Group lowered their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. Benchmark reiterated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, April 17th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Halozyme Therapeutics Price Performance

HALO stock opened at $38.46 on Wednesday. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 52-week low of $29.85 and a 52-week high of $45.00. The stock’s 50 day moving average is $39.79 and its two-hundred day moving average is $37.80. The company has a market capitalization of $4.89 billion, a PE ratio of 18.23, a P/E/G ratio of 0.45 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. boosted its position in Halozyme Therapeutics by 0.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after acquiring an additional 287 shares during the period. First Horizon Advisors Inc. boosted its position in Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 293 shares during the period. Fifth Third Bancorp boosted its position in Halozyme Therapeutics by 2.6% during the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock worth $468,000 after acquiring an additional 308 shares during the period. Commonwealth Equity Services LLC boosted its position in Halozyme Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock worth $619,000 after acquiring an additional 347 shares during the period. Finally, FCF Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 1.9% in the first quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 391 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 in the last three months. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.